Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224260 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03224260 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 33 participants.
The verdict
NCT03224260, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.
Interventions
- OTHER Matched Placebo
- DRUG BMS-986177
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2017-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03224260
The ClinicalTrials.gov registry entry for NCT03224260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matched Placebo is the first listed.
NCT03224260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03224260 about?
NCT03224260 is a clinical study titled "To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants". Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.
What is the current status of trial NCT03224260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-06-28. Estimated completion is 2017-11-07.
What interventions are being tested in trial NCT03224260?
The interventions under investigation include: Matched Placebo (OTHER), BMS-986177 (DRUG).
Who is sponsoring clinical trial NCT03224260?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.